Randomized clinical trials in adults with sickle cell disease.
Clinical Trial . | Outcome . |
---|---|
* Non FDA-approved | |
Multicenter Study of Hydroxyurea in Sickle Cell Anemia15 | Hydroxyurea reduces the frequency of painful episodes, acute chest syndrome, transfusions, hospitalizations |
Preoperative Transfusion in Sickle Cell Disease28 | Simple blood transfusion to increase the Hb level to 10 g/dL is as effective as exchange transfusion to reduce Hb S to 30% |
Prophylactic Transfusion in Pregnancy16 | Prophylactic blood transfusion to increase the Hb level to 10 g/dL compared to transfusion for Hb < 6 g/dL or for emergent indications did not improve obstetrical or perinatal outcomes but reduced the incidence of painful episodes |
Captopril for Albuminuria in Sickle Cell Anemia33 | Captopril reduces albuminuria in normotensive patients |
Poloxamer 188* for Treatment of Acute Vaso-occlusive Crisis12 | Poloxamer 188 reduces the duration of acute painful episodes |
Clinical Trial . | Outcome . |
---|---|
* Non FDA-approved | |
Multicenter Study of Hydroxyurea in Sickle Cell Anemia15 | Hydroxyurea reduces the frequency of painful episodes, acute chest syndrome, transfusions, hospitalizations |
Preoperative Transfusion in Sickle Cell Disease28 | Simple blood transfusion to increase the Hb level to 10 g/dL is as effective as exchange transfusion to reduce Hb S to 30% |
Prophylactic Transfusion in Pregnancy16 | Prophylactic blood transfusion to increase the Hb level to 10 g/dL compared to transfusion for Hb < 6 g/dL or for emergent indications did not improve obstetrical or perinatal outcomes but reduced the incidence of painful episodes |
Captopril for Albuminuria in Sickle Cell Anemia33 | Captopril reduces albuminuria in normotensive patients |
Poloxamer 188* for Treatment of Acute Vaso-occlusive Crisis12 | Poloxamer 188 reduces the duration of acute painful episodes |